Fior Markets launched a study titled “Global Immunoassay Market Product & Service (Reagents & Kits, Analyzers, Software), Technology, Platform, Specimen, Application, End User, Region” and Global Forecast 2018-2025.
The global immunoassay market is expected to grow from USD 20.71 Billion in 2017 to USD 40.29 Billion by 2025 at a CAGR of 8.40%during the forecast period from 2018-2025.Increasing cases of infectious and chronic devices influencing the growth in the medical device market. Increasing healthcare and personal care spending and demand for rapid test result are driving the growth of the market.
DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/376055/request-sample
The reagents & kits segment is dominating the market and was valued around USD 9.94 Billion in 2017
Product and service segment includesreagents & kits, analyzers and software.The reagents & kitssegment is dominating the market andwas valued around USD 9.94 Billion in 2017. Rising demand for non-invasive diagnostics techniques and growing need of reagents are driving the growth of the segment.
ELISPOT is dominating the segment and is expected to attain highest CAGR of 10.73% in forecast period
Technology segment is classified into ELISA, Rapid Tests, western blotting, ELISPOT, immuno-PCR and other technologies. High sensitivity, cost benefits and long term presence in the market of the ELISPOT is contributing to the growth of the segment.
The chemiluminescence immunoassays segment is dominating and was valued around USD 7.86 in 2017
Platform segment is classified into chemiluminescence immunoassays, fluorescence immunoassays, colorimetric immunoassays, radioimmunoassays and other platforms. This growth can be attributed to attribute automation and high-throughput techniques offered by the procedure as compared to others.
The infectious disease segment accounted for the largest market share of 34.31% in 2017
Application segment is divided into infectious diseases, oncology, endocrinology, cardiology, bone & mineral disorders, hematology& blood screening, autoimmune disorders, neonatal screening, toxicology and other applications. Increasing population prone to infections is rising demand of these assays which in turn is driving the growth of the segment.
Hospitals segment is dominating the market in the forecast period
The end user segment includes hospitals, clinical laboratories, pharmaceutical and biotechnology industries, blood banks, research & academic laboratories and others end users. Rising demand for high-sensitivity test and convenient access, increasing demand for rapid test result.
Regional Segmentation Analysis:
The market is analysed on the basis of five regions namely North America, Europe, Asia Pacific, South America, and Middle East and Africa. North region dominated the global hemostasis valve market and generated the largest revenue of USD 9.52Billion in 2017.Due to increasing application of immunoassay techniques in cancer research is a major driver of the market.
Some of the eminent industry players operating in the market include Abbott Laboratories, Siemens, Roche, Sysmex Corporation, Danaher Corporation, bioMérieux, DiaSorin, Ortho Clinical Diagnostics, Bio-Rad Laboratories, Thermo Fisher Scientific, QIAGEN, Becton, Dickinson and Company, Agilent Technologies, Merck, Quidel Corporation, PerkinElmer, Mindray, Bio-Techne Corporationamong others.